Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens

Lymphoma Clinical Trial

Official title:

A Phase IIb, Multicenter, Open-Label, Nonrandomized, Repeat-Dose Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00419081
• Other study ID #: BCX1777-Tio-05-202
• Status: Terminated
• Phase: Phase 2
• First received: January 5, 2007
• Last updated: January 18, 2012
• Start date: July 2006
• Est. completion date: March 2007

Study information

• Verified date: January 2012
• Source: BioCryst Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether Forodesine Hydrochloride is effective in treating patients with relapsed/refractory precursor T-Lymphoblastic Leukemia/Lymphoma who have failed two or more prior treatment regimens.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 100
• Est. completion date: March 2007
• Est. primary completion date: March 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with an unequivocal histologic diagnosis of precursor T-lymphoblastic leukemia/lymphoma (World Health Organization [WHO] classification).

• Failure to have responded to or relapsed after two or more treatment regimens for their disease, one of which could be HSCT.

• Performance status of 2 by Eastern Cooperative Oncology Group (ECOG) criteria (see Appendix A).

• Eighteen years of age and older.

• Life expectancy of at least three months.

• Adequate liver function (aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT] =3 times upper limit of normal), unless related to the underlying leukemia.

• Negative serum or urine pregnancy test within two to seven days prior to the start of study treatment in females of childbearing potential.

• Females of childbearing potential and males must be willing and able to use an adequate method of contraception to avoid pregnancy for the duration of the study in such a manner that the risk of pregnancy is minimized. Acceptable contraceptives include intra-uterine devices (IUDs), hormonal contraceptives (oral, depot, patch, or injectable), and double-barrier methods such as condoms or diaphragms with spermicidal gel or foam.

• Signed informed consent form (ICF) prior to start of any study-specific procedures.

• Willing and able to provide authorization for the use and disclosure of personal health information in accordance with Health Insurance Portability and Accountability Act (HIPAA) policy (U.S. patients only).

Exclusion Criteria:

• Patients with known human immunodeficiency virus (HIV) infection or human T lymphotrophic virus 1 (HTLV-1).

• Patients with active hepatitis B or C infection.

• Patients with clinical evidence of active central nervous system (CNS) leukemia.

• Active serious infection not controlled by oral or intravenous antibiotics.

• Patients with a calculated creatinine clearance of <50 mL/min.

• Prior treatment with any investigational antileukemic or chemotherapy agent within seven days prior to study entry or lack of full recovery from side effects due to prior therapy, independent of when that therapy was given.

• Rapidly progressive disease with compromised organ function judged to be life threatening by the Investigator.

• Concurrent treatment with other antileukemia agents (CNS prophylaxis [e.g., intrathecal methotrexate, cytarabine, or hydrocortisone] and corticosteroid use will not be excluded, but must first be approved by the Medical Monitor) (see Sections 9.2.1 and 9.2.2).

• Pregnant and/or lactating female.

• Patients who cannot swallow or who have chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the product.

• Hypersensitive or intolerant to any component of the study drug formulations.

• Patients who have received prior forodesine treatment.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Lymphoid
• Lymphoma
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Drug:
• Forodesine Hydrochloride Sterile Solution, 5 mg/mL

• Forodesine Hydrochloride Capsules (100 mg)

Locations

Country	Name	City	State
United States	University of Chicago Medical Center	Chicago	Illinois
United States	Liberty Hematology and Oncology	Columbia	South Carolina
United States	University of Texas MD Anderson Cancer Center	Houston	Texas
United States	Louisana State University Health Sciences Center	Shreveport	Louisiana
United States	New York Medical College Division of Oncology	Valhalla	New York

Sponsors (1)

Lead Sponsor	Collaborator
BioCryst Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the rate of complete remission for T lymphoblastic leukemia/lymphoma relapsed or refractory patients. The complete remission rate will be evaluated over the three-month Initial Treatment Period.
Secondary	To determine the rate of CR achieved based on prior HSCT status
Secondary	Assess safety and tolerability
Secondary	Assess survival end points
Secondary	Evaluate the maintenance and duration of response
Secondary	Evaluate the proportion of patients able to proceed to HSCT
Secondary	Evaluate the effects of this forodesine regimen on plasma levels of dGuo
Secondary	Determine the effects of this forodesine regimen on clinical end points
Secondary	Explore potential predictive biomarkers